DUK SAN NEOLUX CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40,350 KRW | +2.67% |
|
+2.93% | -9.33% |
| 05/04 | Nomura Adjusts DukSan Neolux’s Price Target to KRW56,000 From KRW54,000, Keeps at Buy | MT |
| 2023 | Tranche Update on DukSan Neolux Co.,Ltd's Equity Buyback Plan announced on March 2, 2022. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The company's enterprise value to sales, at 4721.05 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -9.33% | 72Cr | - | ||
| +19.99% | 6.8TCr | A- | ||
| -6.03% | 4.59TCr | A- | ||
| +22.27% | 4.37TCr | B+ | ||
| +32.81% | 2.82TCr | A- | ||
| +8.15% | 1.92TCr | C+ | ||
| +14.71% | 1.71TCr | B+ | ||
| -13.18% | 1.47TCr | B+ | ||
| -27.99% | 1.45TCr | A- | ||
| -32.33% | 1.16TCr | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- A213420 Stock
- Ratings Duk San Neolux Co.,Ltd
